RxDoctor Payments Data

Daniel Dietrick

Urology · Towson, MDNPI 1528015914

Payments from drug & device makers

$6,516in general payments, 2019–2025

Across 235 payments — averaging $27.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SN Holdings, LLC$2K
  • Johnson & Johnson$766
  • Astellas Pharma US Inc$397
  • Sumitomo Pharma America, Inc.$389
  • Bayer$315
  • Urovant Sciences Inc$274
  • plus $2K from 33 others

What the payments were for

  • Travel & lodging$1,23419%
  • Food & beverage$5,28281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,516 in reported general payments places this provider in the 55th percentile of 274 urology providers in Maryland.

See all urology providers in Maryland

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron17$14,370
Tamsulosin Hcl68$1,807
Finasteride55$714

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$389$14,37017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 274 urology providers in Maryland.

Other urology in Towson

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →